Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Puma Biotechnology, Inc.NASDAQ: PBYI

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital grows, but more slowly than its trailing trend

Q1 FY2026 other working capital of $12.57M (cash outflow) rose 9.2% year over year, behind the +153.3% change in trailing-twelve-month other working capital.

Context

  • Other working capital amounted to 3.7% of revenue in FY2025, down 3.6 pp from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +9.2% toward the trailing-twelve-month pace of +153.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.57M-215.1% QoQ
Last fiscal yearDec 2025
$8.45M+150.1% YoY
LTMMar 2026
$7.39M+153.3% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.2%——
1 year+150.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
8.45M USD
Year-over-year change
+150.1%
4-year CAGR
-2.2%

Other Working Capital vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +153.3% is the 2nd highest of 10, against a peer median of -98.6%.
  • Other working capital amounts to 3.3% of revenue for PBYI, versus a peer median of 28.8%.
PBYI Competitors
Other Working Capital for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBPNovaBridge BiosciencesLTM Sep 2025CN¥60.15M CNY—-67.4%—
NUVBNuvation Bio Inc.LTM Jun 2026$22.18M USD+273.1%-34.2%13.1%
VSTMVerastem, Inc.LTM Mar 2026$22.05M USD+127.6%+225.8%44.5%
MGNXMacroGenics, Inc.LTM Mar 2026$15.61M USD-279.8%—9.9%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$7.39M USD+153.3%—3.3%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$6.86M USD+42.5%-11.6%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$5.75M USD-304.7%-15.9%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$4.43M USD-387.7%-25.6%843.4%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$3.11M CAD-26.0%——
TNGXTango Therapeutics, Inc.LTM Sep 2026$1.02M USD-98.6%+50.2%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$526K USD-126.6%+20.2%—
Peer median (excluding PBYI) —-98.6%-13.8%28.8%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.13M)2K21.59M30.28M31.11M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
Deferred Income Tax000(7.08M)3.25M
Stock-Based Compensation32.63M11.83M10.25M8.25M6.94M
Change in Working Capital(1.31M)(44.5M)(17.85M)(3.54M)(10.08M)
Accounts Receivables(5.98M)(7.82M)(8.37M)16.35M(21.28M)
Inventory(3.66M)2.58M(2.55M)(1.64M)3.21M
Accounts Payables(902K)(4.73M)449K(1.38M)(453K)
Other Working Capital9.23M(34.52M)(7.38M)(16.86M)8.45M
Other Non-Cash Items7.15M7M1.51M(519K)(358K)
Operating Cash Flow20.65M(15.83M)27.01M38.92M41.8M
Capital Expenditures0(7M)(12.64M)(56K)(71K)
Acquisitions (Net)00000
Purchases of Investments(38.07M)(4.84M)(23.81M)(76.23M)(108.14M)
Sales of Investments27.19M18.94M17.33M55.85M72.02M
Other Investing Activities00(12.5M)00
Investing Cash Flow(10.88M)7.1M(19.13M)(20.44M)(36.19M)
Debt Repayment(1.5M)00(33.33M)(44.44M)
Common Stock Issued012.5M0150K130K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(30.43M)(277K)0(666K)(888K)
Financing Cash Flow(31.93M)12.22M0(33.85M)(45.2M)
Effect of Forex Changes00000
Net Change in Cash(22.16M)3.5M7.88M(15.37M)(39.58M)
Free Cash Flow20.65M(22.83M)14.37M38.86M41.73M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.